These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 33307883)
1. The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. Payandeh Z; Mohammadkhani N; Nabi Afjadi M; Khalili S; Rajabibazl M; Houjaghani Z; Dadkhah M Expert Rev Anti Infect Ther; 2021 Jul; 19(7):899-910. PubMed ID: 33307883 [No Abstract] [Full Text] [Related]
2. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2. Bilal M; Iqbal HMN Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742 [TBL] [Abstract][Full Text] [Related]
3. Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Sultana J; Mazzaglia G; Luxi N; Cancellieri A; Capuano A; Ferrajolo C; de Waure C; Ferlazzo G; Trifirò G Expert Rev Vaccines; 2020 Oct; 19(10):919-936. PubMed ID: 32940090 [No Abstract] [Full Text] [Related]
4. Possible therapeutic agents for COVID-19: a comprehensive review. Elhusseiny KM; Abd-Elhay FA; Kamel MG Expert Rev Anti Infect Ther; 2020 Oct; 18(10):1005-1020. PubMed ID: 32538209 [TBL] [Abstract][Full Text] [Related]
5. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis]. Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: The status and perspectives in delivery points of view. Chung JY; Thone MN; Kwon YJ Adv Drug Deliv Rev; 2021 Mar; 170():1-25. PubMed ID: 33359141 [TBL] [Abstract][Full Text] [Related]
8. Pathogenesis-directed therapy of 2019 novel coronavirus disease. Stratton CW; Tang YW; Lu H J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355 [TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccines: concerns beyond protective efficacy and safety. Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347 [TBL] [Abstract][Full Text] [Related]
11. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. Li CX; Noreen S; Zhang LX; Saeed M; Wu PF; Ijaz M; Dai DF; Maqbool I; Madni A; Akram F; Naveed M; Li JH Biomed Pharmacother; 2022 Feb; 146():112550. PubMed ID: 34959116 [TBL] [Abstract][Full Text] [Related]
12. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19. Li Q; Wang J; Tang Y; Lu H Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059 [TBL] [Abstract][Full Text] [Related]
13. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination - a case report. Paul G; Chad R BMC Pediatr; 2021 Mar; 21(1):138. PubMed ID: 33752624 [TBL] [Abstract][Full Text] [Related]
14. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Russell RL; Pelka P; Mark BL Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067 [TBL] [Abstract][Full Text] [Related]
15. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases? Shi Y; Guo M; Yang W; Liu S; Zhu B; Yang L; Yang C; Liu C Expert Rev Vaccines; 2021 Apr; 20(4):375-383. PubMed ID: 33787439 [TBL] [Abstract][Full Text] [Related]
16. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
17. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center. Aguilar TL; Gorry C MEDICC Rev; 2021 Apr; 23(2):12. PubMed ID: 33974610 [TBL] [Abstract][Full Text] [Related]
19. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303 [TBL] [Abstract][Full Text] [Related]
20. In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform. Russo G; Pennisi M; Fichera E; Motta S; Raciti G; Viceconti M; Pappalardo F BMC Bioinformatics; 2020 Dec; 21(Suppl 17):527. PubMed ID: 33308153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]